been caused by the reinfusion of tumor cells contaminating the graft. This hypothesis is supported by both clinical and laboratory evidence. One of the possible drawbacks to autologous stem cell transplantation in breast cancer (BC) patients is the potential for tumor contamination in the transplanted product. We present a patient with advanced disease Case report who received high-dose chemotherapy (HDC) and PBPC support as consolidation therapy after achieving
of contaminating tumor cells. The samples were immunomay be the cause of recurrence in our patient. The following evidence argues in favor of this hypothesis. First, no cytochemically positive as defined by the murine pancytokeratin monoclonal antibody A45-B/B3 6 in an alkaline signs of recurrence were documented after transplantation in the primary site of metastatic disease, suggesting the phosphatase-anti-alkaline phosphatase assay.
Furthermore, cytokeratin (CK)19 positive cells were efficacy of HDC consolidation. Second, the sites of relapse were suggestive of hematogenous micrometastization. detected by a nested reverse-transcriptase PCR (RT-PCR) assay. 7 Due to the lack of specificity of our method (1/13 Third, the complete response of tumor cells to a second-line treatment was quite unexpected; if these cells had caused a leukapheretic products from patients with hematological malignancies was found CK19 positive), samples were subrelapse so soon after high doses of cytotoxic agents, one would expect them to be chemoresistant. Fourth, cytokeramitted to an independent laboratory. This additional RT-PCR analysis confirmed the presence of the CK19 mRNA tin positive cells were detected in the graft on immunocytochemistry and RT-PCR analyses. signal ( Figure 1) .
It is evident that each of these aspects are per se insufficient to suggest that tumor recurrence was due to graft contamination. In fact mobilization chemotherapy has been Discussion shown to increase the number of BC cells in the circulation 11 and the relapse experienced by patients might be, Several investigators, using a variety of detection methods, have reported neoplastic cells in the peripheral blood in in part, a result of this tumor cell migration. Furthermore, given the often unpredictable natural history of MBC, the substantial numbers of patients with breast cancer.
3, 8 On the other hand, none of these studies has absolutely proven possibility of a tumor response to salvage chemotherapy given at relapse after HDC cannot be completely excluded. that the tumor cells detected have clonogenic capacity in vivo and can therefore concur in sustaining tumor relapse;
However, when looking comprehensively at this patient's clinical history, the possibility of a relapse caused by graft however, this possibility has raised concern among oncologists, and various ex vivo purging techniques have been contamination cannot be overlooked. The biological and clinical relevance of detecting occult developed in order to selectively remove tumor cells from the graft. 9, 10 breast cancer cells in harvested bone marrow or peripheral blood stem cell products remains to be defined. Several The present report suggests that tumor contamination authors have reported that the presence of these cells correlated with a poor outcome 12,13 which may reflect either advanced tumor burden or the metastatic potential of reinfused tumor cells.
The answer to this crucial question may eventually come from gene marking studies or, more realistically, through prospective randomized clinical trials (which are now ongoing) looking at the outcome of patients receiving purged vs unpurged grafts. Until such studies provide this information, procedures designed to detect and purge stem cell harvests of contaminating tumor cells should be considered in order to prevent reinfusion of clonogenic malignant cells.
14 The efficacy of stem cell purging in ameliorating event-free survival has been proved in several hematological malignancies. viability of tumor cells in peripheral blood stem cell collec-
